HIGHLIGHTS
- who: January and collaborators from the Michigan Medicine, of Michigan, United States have published the Article: E3 ligase ligand optimization of Clinical PROTACs, in the Journal: (JOURNAL)
- what: Since PROTAC technology was first identified as a clinical therapeutic strategy, both academia and industry have shown great interest in PROTACs technology.
SUMMARY
The degradation of most damaged and soluble misfolded proteins is achieved by the 26S proteasome through ubiquitin-proteasome system (UPS)-mediated protein degradation (Paiva et_al, 2019; Pohl et_al, 2019; Kawahata et_al, 2020). In the UPS, the proteasome conjugated to a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.